Internal medicine journal
-
Internal medicine journal · Jul 2024
Multicenter StudyLurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme.
Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum-containing therapy. ⋯ This real-world national experience of lurbinectedin post-platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.